Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

ALK-Abelló

208.80 DKK-0.19 %4.9, 16.59
Less than 1K followers

ALK B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
-0.19 %
-2.79 %
-20.37 %
-2.88 %
-8.66 %
+2.76 %
+151.26 %
+33.16 %
+505.22 %

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen.

Read more
Market cap
46.53B DKK
Turnover
29.34M DKK
Revenue
6.31B
EBIT %
26.2 %
P/E
38.67
Dividend yield-%
0.77 %
Revenue and EBIT-%
EPS and dividend
Financial calendar
18.11
2026

Interim report Q3'26

All
Research
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Analyst Comment24.08.2026, 14.38 by
Victor Skriver

ALK: Præsentation af H1 2026 (optagelse)

I dag præsenterede ALK's EVP & CFO, Claus Steensen Sølje, og VP & Head of IR, Per Plotnikof, halvårsregnskabet for H1 2026, strategiske højdepunkter og besvarede spørgsmål fra publikum ved et live online-event.

ALK-Abelló
ALK – Præsentation af H1 2026-regnskab
Webcast24.08.2026, 13.00

ALK – Præsentation af H1 2026-regnskab

ALK forventes at offentliggøre sit H1 2026-regnskab den 20. august 2026. Mandag den 24. august kl. 13.00 kan du møde og stille spørgsmål til ALK's EVP & CFO, Claus Steensen Sølje, og VP & Head of IR, Per Plotnikof, når de præsenterer halvårets finansielle resultater og strategiske højdepunkter.

ALK-Abelló
Analyst Comment24.08.2026, 08.30 by
Victor Skriver

Mød ledelsen i Gubra og ALK og stil dine spørgsmål til dagens investorpræsentationer

I dag afholder vi to online investorevents. Kl. 10:30 præsenterer Gubra CFO Kristian Borbos og Head of Investor Relations Adam Lange halvårsrapporten for H1 2026. Kl. 13:00 præsenterer ALK EVP & CFO Claus Steensen Sølje og VP & Head of Investor Relations Per Plotnikof halvårsrapporten for H1 2026. Tilmeld dig og stil dine spørgsmål allerede nu.

GubraALK-Abelló

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release22.08.2026, 12.23

Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer

ALK-Abelló
Regulatory press release22.08.2026, 12.23

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

ALK-Abelló
Regulatory press release21.08.2026, 14.00

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

ALK-Abelló
Regulatory press release21.08.2026, 14.00

Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer

ALK-Abelló
HCA Morgenbørs 20/08 - Copenhagen Capital CEO-interview og regnskaber i fokus
Video20.08.2026, 09.28 by
Michael Friis, Victor Skriver

HCA Morgenbørs 20/08 - Copenhagen Capital CEO-interview og regnskaber i fokus

Udsigt til flad åbning i Europa, hvor regnskaber kan sætte retningen. Fokus på regnskabsaktuelle ALK, Ascelia Pharma, Gubra, BioPorto og ExprS2ion. Gæst i studiet her til morgen er Copenhagen Capitals direktør, Rasmus Greis.

NovonesisGN Store NordAscelia PharmaBioPortoALK-AbellóGrønlandsbankenDFDSGubraCopenhagen Capital
HCA dagens aktienyheder 20/08/2026: SP Group, GrønlandsBANKEN, GreenMobility, Ascelia Pharma, Gubra, BioPorto, ALK-Abelló og ExpreS2ion Biotech
Analyst Comment20.08.2026, 08.55 by
Michael Friis, Rasmus Køjborg

HCA dagens aktienyheder 20/08/2026: SP Group, GrønlandsBANKEN, GreenMobility, Ascelia Pharma, Gubra, BioPorto, ALK-Abelló og ExpreS2ion Biotech

SP Group køber britiske OGM Moulding for ca. DKK 158 mio. og opjusterer omsætningsforventningerne til 2026. GrønlandsBANKEN leverer solid fremgang på bundlinjen i H1 med et stærkt Q2, der opvejer en svagere start på året. GreenMobility lander flerårig ladeaftale med EDF, hvor franskmændene tager hele investeringen og driftsomkostningerne. Ascelia Pharma halverer driftsunderskuddet i Q2 og har kapital ind i Q2 2027 frem mod FDA-mødet den 9. september. Gubra melder om stærkt klinisk pipeline-momentum, og CRO-forretningen viser tegn på at have fundet bunden. BioPorto ser underliggende NGAL-vækst på 23% og tilføjer seks nye amerikanske hospitaler, mens 2026-guidance fastholdes. ALK-Abelló slår konsensus på både top- og bundlinje i Q2 og løfter bunden af omsætningsguidancen for 2026. ExpreS2ion Biotech rapporterer HER2-antistofrespons hos 12 ud af 13 evaluerbare patienter og ingen dosisbegrænsende toksicitet.

SP GroupGrønlandsbankenGreenMobilityAscelia PharmaGubraBioPortoALK-Abelló
Press release20.08.2026, 07.33

ALK appoints Jacob Glenting as head of Global R&D

ALK-Abelló
Regulatory press release20.08.2026, 07.30

Six-month interim report (Q2) 2026 (unaudited)

ALK-Abelló
Regulatory press release20.08.2026, 07.30

Six-month interim report (Q2) 2026 (unaudited) - English version only

ALK-Abelló
Press release14.08.2026, 12.23

ALK’s tree pollen and house dust mite tablets now recommended by NICE for paediatric treatment in the UK health system

ALK-Abelló
Press release13.08.2026, 16.06

Invitation to the presentation of ALK’s first six months (Q2) 2026 results on Thursday, 20 August 2026

ALK-Abelló
Press release13.08.2026, 16.06

Invitation til præsentation af ALK’s regnskab for første halvår (Q2) 2026 torsdag den 20. august 2026

ALK-Abelló
Analyst Comment06.08.2026, 08.11 by
William Jørck

Today's stock news 08/06/2026: ALK-Abelló

ALK-Abelló is now launching the nasal adrenaline spray neffy® 2 mg in Canada following approval from Health Canada in April. The needle-free product will be the first epinephrine treatment in spray form for anaphylaxis in adults and children (≥30 kg). Canada is set to become ALK's largest market outside Europe, with up to 2.5 million citizens affected by severe allergies. The launch does not change the company's 2026 guidance.

ALK-Abelló
Press release05.08.2026, 13.09

Market launch of the nasal adrenaline spray, neffy®, for treatment of adults and children with severe allergies in Canada

ALK-Abelló
Analyst Comment26.06.2026, 09.05 by
Victor Skriver

Dagens aktienyheder 26/06/2026: ALK-Abelló

Dagens aktienyheder 26/06/2026: ALK-Abelló

ALK-Abelló
Press release04.06.2026, 08.30

ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026

ALK-Abelló
Regulatory press release01.06.2026, 21.20

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

ALK-Abelló